INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Observational study / 2018

Elevated serum vitamin B12 levels were associated with significantly shorter survival times in patients with metastatic cancer.

A retrospective chart review of 523 metastatic cancer patients examined serum vitamin B12 as a prognostic factor. Median survival time was 1.8 months in the high B12 group (>911 pg/mL) compared to 5.1 months in the normal B12 group (211-911 pg/mL) (p < 0.001). Among patients without liver lesions, median survival was 2.1 months in the high group versus 6.1 months in the normal group (p < 0.001). Multivariate analysis identified serum vitamin B12 as an independent prognostic factor for overall survival (HR: 1.62; 95% CI: 1.34-1.96, p < 0.001).

Shows an association, not proof of cause and effect.

Study type
Retrospective cohort study
Who was studied
523 metastatic cancer patients
What was measured
Survival time / overall survival

THE PAPER

Elevated Serum Vitamin B12 Levels as a Prognostic Factor for Survival Time in Metastatic Cancer Patients: A Retrospective Study.

Oh HK, Lee JY, Eo WK, Yoon SW, Han SN. Nutr Cancer, 2018.

PubMed 29220583 ↗DOI 10.1080/01635581.2018.1397711 ↗

CancerNutrients & adequacy

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.